地塞米松对新辅助化疗后乳腺癌患者术后恶心呕吐发生率的影响

doi:10.3969/j.issn.1671-167X.2015.04.027

摘要/Abstract

摘要：

目的：评估地塞米松对新辅助化疗（术前化疗）后乳腺癌改良根治术术后恶心呕吐（postoperative nausea and vomiting, PONV）的预防效果。方法：新辅助化疗后行乳腺癌改良根治术的女性乳腺癌患者280例，18~60岁，随机分为两组，每组140例：（1）D组：实验组，术前给予10 mg地塞米松静脉滴注；（2）C组：对照组，术前给予2 mL生理盐水作为安慰剂静脉滴注。每组患者再分为两亚组，每组70例，分别应用丙泊酚全凭静脉麻醉(total intravenous anesthesia, TIVA)（P亚组）和七氟醚维持吸入全身麻醉（S亚组）。所有患者均进行标准的全身麻醉操作，手术结束前30 min静脉滴注昂丹司琼(ondansetron) 8 mg。随访术后24 h内患者恶心呕吐的发生率，并对PONV的影响因素进行Logistic回归分析。检测因素包括年龄、体重指数（body mass index, BMI）、手术时间、术后疼痛程度、晕动病史/既往PONV史、是否应用地塞米松以及麻醉方法。结果：术后24 h内D组患者恶心呕吐的发生率明显低于C组患者（11.4% vs. 20.7%，P=0.034）；术后0~2 h D组患者PONV的发生率低于C组患者（1.4% vs. 6.4%，P=0.031）；术后2~24 h D组患者PONV的发生率与C组患者差异无显统计学意义（10.7% vs. 17.9%，P=0.088）。术后24 h内各时段，D组与C组内丙泊酚全凭静脉麻醉亚组与吸入麻醉亚组PONV的发生率比较差异均无统计学意义（P>0.05）。Logistic回归分析显示地塞米松对新辅助化疗后乳腺癌改良根治术患者术后恶心呕吐有预防效果（OR=0.447，P=0.030），晕动症/PONV病史是术后恶心呕吐的危险因素（OR=15.730，P＜0.001）。结论：术前应用地塞米松可明显降低新辅助化疗后乳腺癌改良根治术患者术后恶心呕吐的发生率。

关键词: 手术后恶心呕吐, 新辅助治疗, 地塞米松, 丙泊酚, 乳房切除术, 改良根治性

Abstract:

Objective：To evaluate the influence of dexamethasone on the incidence of postoperative nausea and vomiting (PONV) in patients undergoing modified radical mastectomy with neoadjuvant chemotherapy. Methods:In a prospective trial, 280 female (18-60 years) breast cancer patients undergoing modified radical mastectomy with neoadjuvent chemotherapy were randomized to two groups: one with dexamethasone (Group D) and one without dexamethasone (Group C, n=140). In each group, anesthesia was maintained with volatile anesthesia or total intravenous anesthesia (TIVA): TIVA (propofol) without dexamethasone (Subgroup CP); volatile anesthesia (sevoflurane) without dexamethasone (Subgroup CS); TIVA with 10 mg dexamethasone intravenously before anesthetic induction (Subgroup DP); volatile anesthesia with 10 mg dexamethasone intravenously before anesthetic induction (Subgroup DS). A standard general anesthetic technique was used. All the patients received 8 mg of ondansetron intravenously 30 minutes before the end of surgical procedures. The incidence of PONV during the 24-hour postoperative period was recorded. A Logistic regression analysis was conducted to examine relevant factors for PONV . The tested factors were: age, body mass index (BMI), duration of surgery, postoperative pain, history of motion sickness/PONV, with or without dexamethasone and anesthetic regimen.Results:There was a significant lower incidence of PONV in the patients who received dexamethasone than in those who received placebo during the 24-hour postoperative period (11.4% vs. 20.7%，P=0.034). In the early postoperative period (0-2 h) dexamethasone reduced the incidence of PONV ( 1.4%vs.6.4%， P=0.031）,but in the late postoperative period (2-24 h) the difference of the incidence was insignificantly (10.7% vs. 17.9%， P=0.088). No differences were found between TIVA and volatile anesthesia in the 24hour postoperative period. Dexamethasone was effective to prevent PONV（OR=0.447，P=0.030）, and history of PONV or motion sickness was the risk factor of PONV (OR=15.730，P＜0.001). Conclusion:Dexamethasone prevents PONV effectively in patients undergoing modified radical mastectomy with neoadjuvant chemotherapy, and TIVA cannot decrease the incidence of PONV in the 24hour postoperative period in those patients.

Key words: Postoperative nausea and vomiting, Neoadjuvant therapy, Dexamethasone, Propofol, Mastectomy, modified radical

中图分类号:

R614.2

李志红, 刘丹, 何自静, 范志毅. 地塞米松对新辅助化疗后乳腺癌患者术后恶心呕吐发生率的影响[J]. 北京大学学报(医学版), 2015, 47(4): 685-689.

LI Zhi-Hong, LIU Dan, HE Zi-Jing, FAN Zhi-Yi. Influence of dexamethasone on the incidence of postoperative nausea and vomiting in breast cancer patients with neoadjuvant chemotherapy[J]. Journal of Peking University(Health Sciences), 2015, 47(4): 685-689.

参考文献

相关文章 10

[1]	王立新,许晓,倪耀丰,孙海涛,余日月,魏世成. 载药脂质体修饰的聚醚醚酮植入物的抑菌和骨整合性能[J]. 北京大学学报（医学版）, 2021, 53(4): 758-763.
[2]	张威,叶颖江,任仙文,黄晶,申占龙. 利用转录组二代测序探索直肠癌术前放化疗的敏感性分子特征[J]. 北京大学学报（医学版）, 2019, 51(3): 542-547.
[3]	张喆，居瑞军，李学涛，张东晓，吴仁荣，陈学军，吕万良. 葡萄糖基化丙泊酚溶液型注射剂在大鼠体内的药物动力学[J]. 北京大学学报(医学版), 2015, 47(5): 846-852.
[4]	马泽云, 王衣祥. 建立大鼠双膦酸盐相关颌骨骨坏死模型并初步分析其发病原因[J]. 北京大学学报（医学版）, 2014, 46(6): 945-949.
[5]	关明，王恩博，刘宇，张伟. 丙泊酚靶控输注联合芬太尼静脉镇静拔除下颌阻生智齿的效果评价[J]. 北京大学学报（医学版）, 2014, 46(1): 107-110.
[6]	杨璐, 魏滨, 张利萍, 毕姗姗, 卢炜, 郭向阳. 丙泊酚和瑞芬太尼在抑制强直电刺激中的药效学相互作用[J]. 北京大学学报（医学版）, 2010, 42(5): 547-553.
[7]	林琴, 王广发, 汤秀英, 邹水兰. 地塞米松对内毒素致急性肺损伤大鼠肺的保护作用[J]. 北京大学学报（医学版）, 2006, 38(4): 393-396.
[8]	许川雅, 吴新民, 蒋建渝. 老年患者靶控输注瑞芬太尼和丙泊酚的临床评价[J]. 北京大学学报（医学版）, 2005, 37(5): 513-515.
[9]	王治军, 许幸, 吴新民. 地塞米松、甘露醇对大鼠全脑缺血再灌注损伤的治疗作用[J]. 北京大学学报（医学版）, 2003, 35(3): 303-306.
[10]	范志毅, 马琼, 王庚. 丙泊酚与硫喷妥钠全麻诱导的血流动力学及儿茶酚胺反应的比较[J]. 北京大学学报（医学版）, 2001, 33(6): 576-576.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2]	郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3]	卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[4]	袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[5]	徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[6]	董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报（医学版）, 2009, 41(1): 109 -111 .
[7]	祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[8]	李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
[9]	丰雷, 王玉凤, 曹庆久. 哌甲酯对注意缺陷多动障碍儿童平衡功能影响的开放性研究[J]. 北京大学学报（医学版）, 2007, 39(3): 304 -309 .
[10]	刘津, 王玉凤. 父母培训对共患对立违抗性障碍的注意缺陷多动障碍的作用[J]. 北京大学学报（医学版）, 2007, 39(3): 310 -314 .